Head-to-head · The Match Score
CoreAge Rx vs Hims & Hers
Both scored on the same six-factor Match Score. CoreAge Rx wins this matchup with a 91 to 75 edge.
CoreAge Rx
Grade A−
People who want one flat monthly price on either molecule that doesn't climb as the dose goes up, and who don't need a brand-name drug or a pill.
Visit CoreAge RxHims & Hers
Grade C
Cash-pay patients who want FDA-approved Wegovy or Zepbound inside a polished app with round-the-clock messaging.
Visit Hims & HersFactor by factor
The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.
Price, coverage & formulary
| Detail | CoreAge Rx | Hims & Hers |
|---|---|---|
| Semaglutide | $99/mo at every dose | $298/mo (starting dose, all-in with the membership, brand-name) |
| Tirzepatide | $149/mo at every dose | $448/mo (starting dose, all-in with the membership, brand-name) |
| Coverage | U.S. only — restrictions vary by state and therapy, list not published | Most states (GLP-1s not yet offered in all 50) |
| Brand-name access | Not listed | Yes |
| Oral / sublingual | Not listed | Yes |
| Match Score | 91 · A− | 75 · C |
CoreAge Rx edges out Hims & Hers, 91 to 75 on the default Match Score. Compounded semaglutide at $99 and tirzepatide at $149 a month, the same price at every dose, with no membership fee and a full refund if the doctor doesn't approve you.
Hims & Hers is still a fair pick if its strengths line up with yours — best for: Cash-pay patients who want FDA-approved Wegovy or Zepbound inside a polished app with round-the-clock messaging.
Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.
More head-to-heads
Or browse alternatives to CoreAge Rx and all comparisons.
Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.